AstraZeneca AB Release: Fourth Quarter and Full Year Results 2011

Published: Feb 02, 2012

LONDON--(BUSINESS WIRE)--Regulatory News:

AstraZeneca (STO:AZN)(LSE:AZN):

Revenue for the full year was down 2 percent at constant exchange rates (CER) at $33,591 million.

-Strong double-digit sales growth at CER for Crestor, Seroquel XR and Symbicort; Emerging Markets revenue increased by 10 percent at CER in the fourth quarter and for the full year.

Back to news